Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough

Abstract EN

Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an abnormal accumulation of extracellular matrix components.

Despite its slow progression, it leads to organ malfunction.

Fibrosis can affect almost any tissue.

Due to its high frequency, in particular in the heart, lungs, liver, and kidneys, many studies have been conducted to find satisfactory treatments.

Despite these efforts, current fibrosis management therapies either are insufficiently effective or induce severe adverse effects.

In the light of these facts, innovative experimental therapies are being investigated.

Among these, cell therapy is regarded as one of the best candidates.

In particular, mesenchymal stromal cells (MSCs) have great potential in the treatment of inflammatory diseases.

The value of their immunomodulatory effects and their ability to act on profibrotic factors such as oxidative stress, hypoxia, and the transforming growth factor-β1 pathway has already been highlighted in preclinical and clinical studies.

Furthermore, their propensity to act depending on the microenvironment surrounding them enhances their curative properties.

In this paper, we review a large range of studies addressing the use of MSCs in the treatment of fibrotic diseases.

The results reported here suggest that MSCs have antifibrotic potential for several organs.